| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744978 | Clinical Microbiology and Infection | 2017 | 20 Pages |
Abstract
RADAR favoured β-lactam over fluoroquinolone therapy for community-acquired pneumonia. Although RADAR required fewer patients than conventional non-inferiority analysis, the statistic was less sensitive to detrimental outcomes.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
V.A. Schweitzer, M. van Smeden, D.F. Postma, J.J. Oosterheert, M.J.M. Bonten, C.H. van Werkhoven,